Need Help With This Product?
Our specialists are here to help you find the best product for your application.
iCell Cardiomyocytes², 01434 Serum-Free Kit
Products
Kits
- Cryopreserved iCell Cardiomyocytes², 01434
- 30 ml Plating Medium
- 100 ml Maintenance Medium
- 100 ml iCell Cardiomyocytes Serum-Free Medium
- User's Guide
genetic status
Quantity (Cells Per Vials)
Catalog #
Catalog #:
Cardiomyocytes² Serum-Free Kits differentiated from human iPS cells, frozen
From
$1,858.00
Product Overview
iCell® Cardiomyocytes2 from FUJIFILM Cellular Dynamics, provide relevant biology and rapid workflows making them powerful tools for safety, toxicology, and drug discovery research. FCDI offers a full suite of cardiomyocyte media that are all DMEM-based with the same physiological ion concentrations and mature glucose-free energy source. Rigorously designed and quality controlled to work with iCell Cardiomyocytes2, these media provide researchers the ability to seamlessly switch between serum-containing, serum-free, and albumin-free conditions, enabling acute and chronic studies.
iCell Cardiomyocytes Serum-Free Medium is a serum-free and glucose-free medium formulation optimized for iCell Cardiomyocytes2 assays for up to 14 days. iCell Cardiomyocytes Serum-Free Medium can be used for both acute and chronic repeat dosing experiments.
Components:
Our regular business hours are 9:00am to 5:00pm Central Time (USA)
Need Help With This Product?
Our specialists are here to help you find the best product for your application.
Our regular business hours are 9:00am to 5:00pm Central Time (USA)
Technical Docs
PROTOCOLS
Application Notes
A robust and reproducible QPatch® II assay for Nav1.5 measurements
Application Protocols
Using Liposome-mediated Transfection for Gene Delivery
USER DOCS
User's Guides
iCell Cardiomyocytes2
Datasheet
iCell Cardiomyocytes2
Safety Data Sheet
iCell Cardiomyocytes Serum-Free Medium Safety Data Sheet - Asia
Safety Data Sheet
iCell Cardiomyocytes Serum-Free Medium Safety Data Sheet
Performance Data
iCell Cardiomyocytes and iCell Cardiomyocytes2 Maintain High Purity, Viability, and Functional Properties Across Platforms When Cultured in iCell Cardiomyocytes Serum-Free Medium (iCSFM), iCell CardioTox Assay Medium (iCTAM) Similar to iCell Cardiomyocytes and iCell Cardiomyocytes2 Cultured in iCell Cardiomyocytes Maintenance Medium (iCMM)
(A) High cardiac purity by cTNT flow cytometry, and (B) High viability as indicated by CyQUANT Direct Cell Proliferation Assay (normalized to maximal response per experiment and reported as % iCMM) at end of recommended workflow: D14 cultured in iCMM or iCSFM; D11 cultured in iCTAM. (Purity n=3-6; Viability n= 64-90). (C) Using the xCELLigence CardioRTCA, iCell Cardiomyocytes2 cultured in iCSFM or iCTAM maintained comparable cell index (measure of cell attachment and health) and beat rate (not shown) to those cultured in iCMM (D7 n=24-48; D11 n=9-18). (D) Using the Maestro Pro MEA platform, iCell Cardiomyocytes2 cultured in iCSFM or iCTAM maintained comparable percent total active electrodes (not shown), beat rate, low beat rate irregularity, and field potential duration (FPD corrected to beat rate) to those cultured in iCMM. We recommend iCTAM for up to 4 days as we observed a reduction in beat rate with cells cultured in iCTAM for 7d. (n=24-48) (Data with iCell Cardiomyocytes not shown)
Figure 1: iCell Cardiomyocytes2 Maintain High Purity, Viability, and Functional Properties Across Platforms When Cultured in iCell Cardiomyocytes Serum-Free Medium (iCSFM), iCell CardioTox Assay Medium (iCTAM) Similar to iCell Cardiomyocytes2 Cultured in iCell Cardiomyocytes Maintenance Medium (iCMM)
Figure 2: iCell Cardiomyocytes2 Maintain Comparable Contractility and Electrophysiology Across Serum-Free Media
iCell Cardiomyocytes2 Maintain Comparable Contractility and Electrophysiology Across Serum-Free Media
Representative traces for (A) Impedance measurements (xCELLigence), (B) Field potential (with T-wave marked) and (C) Action potential (LEAP) traces from Day 7, 4h after media change. Note: In (B) and (C) the cells had been treated with 0.1% DMSO vehicle control.
Characteristics of iCell Cardiomyocytes2 Contractile Parameters Cultured in iCell Cardiomyocytes Serum-free Medium on the FLEXcyte 96 System
(A) Comparison of mean beats are shown of iCell Cardiomyocytes2 cultured in iCell Cardiomyocytes Serum-free Medium (iCSFM) and serum containing iCell Cardiomyocytes Maintenance Medium (iCMM) 24 hours after medium switch. (B) A bar graph showing contractile parameters (amplitude, beat rate, beat duration, area under curve, upstroke and downstroke slopes) of iCell Cardiomyocytes² cultured in iCell Cardiomyocytes Serum-free Medium after 24 hours. Data is normalized to iCell Cardiomyocytes² cultured in iCell Cardiomyocytes Maintenance Medium. (Data kindly provided by Innovitro and Nanion Technologies)
Figure 3: Characteristics of iCell Cardiomyocytes2 Contractile Parameters Cultured in iCell Cardiomyocytes Serum-free Medium on the FLEXcyte 96 System
Figure 4: Comparative LEAP Traces of Cardiomyocyte Media Cultured Cells
Comparative LEAP Traces of Cardiomyocyte Media Cultured Cells
Representative LEAP traces recorded from iCell Cardiomyocytes2 treated with DMSO (control) or Drug (Nifedipine (50nM) top panels, E4031 (30nM), bottom panel) when cultured in iCMM (left), iCSFM (middle) or iCTAM (right). iCell Cardiomyocytes2 were thawed and plated according to User's Guide and cultured until DIV7 in iCMM. On DIV7 some of the wells were washed and fed with iCSFM (for 4 hours and then dosed) or iCTAM (cultured until DIV11 and then dosed).